Department of Physiology, National and Kapodistrian University of Athens, Greece.
Departments of Physiology and Pathophysiology, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Greece.
Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):185-191. Epub 2019 Jul 11.
Type I interferons (IFN) have long been recognised as mediators of innate immune defense mechanisms against viral threats. Robust evidence over the last 15 years revealed their significant role in the pathogenesis of systemic autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Despite the progress, methods of detection, initial triggers, biological functions and clinical associations in the setting of autoimmunity remain to be fully clarified. As therapeutic options for SS are currently limited, neutralising specific targets of the type I IFN pathway seems a promising option. In this review we summarise the current evidence regarding the role of type I IFN in SS.
I 型干扰素（IFN）长期以来被认为是机体针对病毒威胁的固有免疫防御机制的介质。在过去的 15 年中，大量证据表明其在系统性自身免疫性疾病的发病机制中具有重要作用，包括系统性红斑狼疮（SLE）和干燥综合征（SS）。尽管取得了这些进展，但在自身免疫的背景下，其检测方法、初始触发因素、生物学功能和临床关联仍有待充分阐明。由于目前 SS 的治疗选择有限，因此针对 I 型 IFN 途径的特定靶点进行中和似乎是一种很有前途的选择。在这篇综述中，我们总结了目前关于 I 型 IFN 在 SS 中的作用的证据。
